LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Kodu・Aktsiate loetelu・MacroGenics Inc

MacroGenics Inc

Suletud

SektorTervishoid

4.15 19.6

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.43

Max

4.3

Põhinäitajad
By Trading Economics
Sissetulek	-31M -14M
Müük	-32M 41M
Aktsiakasum	-0.22
Kasumimarginaal	-34.333
Töötajad	293
EBITDA	-37M -15M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+83.48% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	19. mai 2026

Turustatistika
By TradingEconomics
Turukapital	65M 188M
Eelmine avamishind	-15.45
Eelmine sulgemishind	4.15

Uudiste sentiment

By Acuity

35%

65%

112 / 346 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

1.47 / 1.64 Toetus ja vastupanu

MacroGenics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. mai 2026, 22:44 UTC

Omandamised, ülevõtmised, äriostud

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14. mai 2026, 22:27 UTC

Omandamised, ülevõtmised, äriostud

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14. mai 2026, 22:12 UTC

Tulu

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14. mai 2026, 21:52 UTC

Omandamised, ülevõtmised, äriostud

LVMH to Sell Marc Jacobs

15. mai 2026, 00:00 UTC

Tulu

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14. mai 2026, 23:57 UTC

Omandamised, ülevõtmised, äriostud

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14. mai 2026, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14. mai 2026, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14. mai 2026, 23:56 UTC

Market Talk

Gold Prices Rise on Strong Demand -- Market Talk

14. mai 2026, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14. mai 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

14. mai 2026, 23:50 UTC

Market Talk

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14. mai 2026, 23:47 UTC

Tulu

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14. mai 2026, 23:47 UTC

Tulu

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14. mai 2026, 23:46 UTC

Tulu

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14. mai 2026, 23:46 UTC

Tulu

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14. mai 2026, 23:28 UTC

Market Talk

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14. mai 2026, 23:00 UTC

Market Talk

Australia's One Nation Party Leads In The Polls -- Market Talk

14. mai 2026, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

14. mai 2026, 22:46 UTC

Market Talk

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14. mai 2026, 22:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. mai 2026, 22:35 UTC

Market Talk

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14. mai 2026, 22:11 UTC

Omandamised, ülevõtmised, äriostud

LVMH Agrees to Sell Marc Jacobs -- WSJ

14. mai 2026, 22:06 UTC

Market Talk

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14. mai 2026, 22:04 UTC

Tulu

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14. mai 2026, 22:04 UTC

Tulu

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14. mai 2026, 22:04 UTC

Tulu

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14. mai 2026, 22:00 UTC

Tulu

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14. mai 2026, 21:55 UTC

Tulu

Nu Holdings 1Q EPS 18c >NU

14. mai 2026, 21:55 UTC

Tulu

Nu Holdings 1Q Rev $4.97B >NU

Võrdlus sarnastega

Hinnamuutus

MacroGenics Inc Prognoos

Hinnasiht

By TipRanks

83.48% tõus

12 kuu keskmine prognoos

Keskmine 6.33 USD 83.48%

Kõrge 9 USD

Madal 4 USD

Põhineb 5 Wall Streeti analüütiku instrumendi MacroGenics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi MacroGenics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.47 / 1.64Toetus ja vastupanu

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

112 / 346 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.